October 3, 2022 05:34 AM EDTUpdated 07:29 AM
R&D

#AAO22: On the heels of PhI­II launch, Au­ra de­tails sec­ond ad­min­is­tra­tion route of its oc­u­lar on­col­o­gy drug

Kyle LaHucik

Senior Reporter

CHICA­GO — Ahead of its fourth quar­ter piv­otal tri­al launch, Au­ra Bio­sciences de­tailed some in­ter­im da­ta from its on­go­ing Phase II tri­al of an eye …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times